Phosphorylated α-synuclein in Parkinson's disease. - Wikidata - thesis-toulmin - TriplyDB

Phosphorylated α-synuclein in Parkinson's disease.

Phosphorylated α-synuclein in Parkinson's disease.

http://www.wikidata.org/entity/Q30510167

about

Current status of biomarker research in neurology Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis Glia and alpha-synuclein in neurodegeneration: A complex interaction Mitochondrial dysfunction and oxidative stress in Parkinson's disease Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsy Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data.Bioactive marine drugs and marine biomaterials for brain diseases Towards translational therapies for multiple system atrophy Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunction.Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy.Unbiased approaches to biomarker discovery in neurodegenerative diseases Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.Cognition in movement disorders: where can we hope to be in ten years?Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.Progression of Regional Microstructural Degeneration in Parkinson's Disease: A Multicenter Diffusion Tensor Imaging Study Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia.Role of Ser129 phosphorylation of α-synuclein in melanoma cells Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology.Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.Biomarkers of Parkinson's disease: current status and future perspectives.Cerebrospinal fluid biomarkers in Parkinson disease.Recent developments in biomarkers in Parkinson disease Modeling Lewy pathology propagation in Parkinson's disease.Neuropathology of multiple system atrophy: new thoughts about pathogenesis.Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

P2860

Q26744505-C5CEA1FB-140C-4292-9E2F-D975D220F144 Q26770708-70086758-337D-4284-A859-7ACFAFD08B2B Q26785974-A5CCFD6D-47A4-4E8A-8BB2-7ABC6D58B313 Q26851153-9ED48F50-EE15-4F76-93E7-319A2C5D056C Q27014051-FFF2F29A-5FA8-4EFF-A926-4658ECCCB1F4 Q27311994-1A379309-D9E0-4564-B22C-1C9FE7CBBFB4 Q27686837-B239AF16-350F-4BB0-BA98-E4E789583022 Q28083203-AE2510A0-BBEA-4BF4-B5ED-8E9DAD9B4B59 Q28087330-7F473580-58AD-4C58-B30B-3D00D33C586C Q30538175-29AD1291-6120-4E8E-BE61-D98907C82766 Q30659251-BA1BAB42-AD04-401F-BC2F-3C3AF4E546C6 Q31096478-717CCE0D-D8E9-450B-B958-27EC5E56DD2F Q33736687-6CED91A8-701A-472D-B6B2-0F1513576017 Q33797532-804EEB4A-454E-4B9D-9F72-AD33E86E7969 Q33970870-CF87D8A5-0E32-4915-8750-CCAC1E501969 Q34237637-362EE3A6-4ADE-4FAB-B8EF-98ACF08CB118 Q34356116-9AE76C42-BCD5-4936-A445-DE2A3AA28576 Q34460662-91ED576D-F4E6-46F6-8355-F8FF646F1D85 Q34625773-99802775-2500-40F4-AC94-3414C51C57C9 Q34625918-9425418F-D13B-4818-ABA9-0FD96A399D29 Q34714560-2FE2893D-B2DF-4ED4-BF21-EEB0E3F3A621 Q35211553-7097014E-DA12-4951-B81B-722BB1D8C155 Q35897340-16AD2787-C51D-40D5-8BB4-794C838D3F95 Q36109452-DEEE16A8-6454-4DB8-9671-CC9E45BA39BE Q36178546-B630D3F2-0E15-478F-B6F1-98B86CF4BDC5 Q36245278-009015BC-382A-466A-9BB2-2EE6DC6FB135 Q36384748-FDAF6CDF-57F1-4CC5-B822-AD466EADF4C1 Q36731472-D81BEC67-BA9D-4A3B-9FFF-94AE2C28B264 Q37038032-E1610EF9-D9E1-4AEA-BD8D-ECEE467C6B5B Q37137895-11346C11-049C-4454-AC81-F21420D063C4 Q37228718-3251DD21-5A37-4872-9B2D-2AA7315EF55A Q37276472-DF38D6FA-3954-4B85-BA71-B97972A57A0C Q37388974-3EA0244C-2B53-4F16-81AD-859A8763BB9B Q37451440-0B618BE3-E2E5-4CEA-8EAC-10EC03007A83 Q38043841-183A0ECC-1515-4BD9-A110-1A838CA008FA Q38082586-7F1F1A79-41FA-48CC-9639-CBDEACFFFA39 Q38119095-D8E917CC-BE76-440B-8559-43B7C08DA5F2 Q38164894-5F3EDD25-260C-49D8-910C-735F454E1E05 Q38258246-1176F478-F013-40B8-BF8F-279A9C52F866 Q38271572-F5859635-2CAD-4D98-A517-A850F7AF9413

P2860

Phosphorylated α-synuclein in Parkinson's disease.

http://www.wikidata.org/entity/Q30510167

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phosphorylated α-synuclein in Parkinson's disease.

@ast

Phosphorylated α-synuclein in Parkinson's disease.

@en

type

label

Phosphorylated α-synuclein in Parkinson's disease.

@ast

Phosphorylated α-synuclein in Parkinson's disease.

@en

prefLabel

Phosphorylated α-synuclein in Parkinson's disease.

@ast

Phosphorylated α-synuclein in Parkinson's disease.

@en

P1433

Q30510167-63FE1C0D-5E3D-4168-9DBA-818F263FA182

P1476

Q30510167-399801F8-0811-49FB-838B-5453A85BB95D

P2093

Q30510167-0EC32DE6-5DD5-4B15-8652-80E63B0AEFFF

Q30510167-23703D4B-B207-4B5B-99C9-29695DA3852A

Q30510167-32826C20-ABB4-42AB-B701-5CB1AD4E8D87

Q30510167-36902859-F395-4EC2-8760-926742E9A394

Q30510167-3EFD25AE-7ADD-431E-B2A5-FEF7A6778D47

Q30510167-54342D8E-CF21-40DE-B4F9-843E038899DD

Q30510167-577076D3-44EB-48C0-A134-0DE5A35362DD

Q30510167-8D39A2A6-09B8-40EA-B3B1-93665C513AA0

Q30510167-911BB722-151A-4D0F-8B87-585A0F72B38D

Q30510167-9FC18295-A659-47AA-8DD6-67F6A77DDCB8

P2860

Q30510167-01EA6F61-3C46-4F0B-B377-ED416BC71602

Q30510167-02E5453F-A431-4024-8731-50C2153EE8ED

Q30510167-0C056D43-2FC8-426D-A8B8-45BE12E7174E

Q30510167-13DC8526-209F-4B85-B91B-EEBE722A61BF

Q30510167-1BA91992-2B96-4E4F-820E-5782C7AD0170

Q30510167-21A70885-0069-45E2-AF41-1C40D7B18D46

Q30510167-24C8602B-3D5C-40D5-BD94-20F465D1D466

Q30510167-2D7D3D53-3EC7-44FF-93FB-0758857F7B83

Q30510167-2E57A2D8-6B66-432F-A495-F7B86FD22122

Q30510167-30105084-87AD-4004-BB96-FD99A8189BFB

P304

Q30510167-91CEDDCB-C0A2-4D2F-AF3C-A250E1C29320

P31

Q30510167-B5DDB6BB-ED3F-48F2-9919-06D667305A29

P356

Q30510167-92510814-3750-4D62-8E4A-AAABB8B0D005

P407

Q30510167-2A7179C1-2B94-4D1E-AB0B-878150FFB179

P433

Q30510167-525409F6-723A-4921-91C3-7A50A2DEF397

P478

Q30510167-0D7052D5-056A-4639-BD45-7782412C0EDC

P50

Q30510167-2041D5D6-0F3F-4820-A4F8-76372D81D374

Q30510167-862D2A48-6CC9-463D-B9B7-8F27115AD154

Q30510167-9C4CCFF8-9F69-4AE5-A9BC-662438CFD74D

Q30510167-DABA8A25-7F99-4007-834D-72AFC12A868A

Q30510167-E8B8AAE9-878C-4D14-80E5-95C98EB0BA03

P577

Q30510167-3BDDB2B6-AA0A-400E-99E8-242F4939E660

P5875

Q30510167-299CF0A8-2A8D-4E44-AA68-7ED266F60261

P698

Q30510167-130FD984-872F-48B6-A106-C829D10B6A71

P921

Q30510167-4C5E3F2D-8570-4255-B199-A0F8B634496B

Q30510167-CADAA9F1-FAF6-4886-A437-3D28184E98B6

Q30510167-CE606982-A8B0-4384-B694-BF4B5EDC531A

P932

Q30510167-DFD9BEA7-9DCC-48A2-AE3C-D9B72BD583EE

P356

SCITRANSLMED.3002566

P1433

Science Translational Medicine

P1476

Phosphorylated α-synuclein in Parkinson's disease.

@en

P2093

Andrew D Siderowf

http://www.w3.org/2001/XMLSchema#string

Catherine Pan

http://www.w3.org/2001/XMLSchema#string

David S Goldstein

http://www.w3.org/2001/XMLSchema#string

Douglas Galasko

http://www.w3.org/2001/XMLSchema#string

Elaine R Peskind

http://www.w3.org/2001/XMLSchema#string

Howard Hurtig

http://www.w3.org/2001/XMLSchema#string

Hui Yang

http://www.w3.org/2001/XMLSchema#string

James B Leverenz

http://www.w3.org/2001/XMLSchema#string

Karin Srulijes

http://www.w3.org/2001/XMLSchema#string

Kathryn A Chung

http://www.w3.org/2001/XMLSchema#string

P2860

Second consensus statement on the diagnosis of multiple system atrophy

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

Alpha-synuclein in Lewy bodies

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filaments

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

Consensus statement on the diagnosis of multiple system atrophy.

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.

P304

121ra20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3002566

http://www.w3.org/2001/XMLSchema#string

P407

P433

121

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Cyrus P Zabetian

John Q. Trojanowski

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221842169

http://www.w3.org/2001/XMLSchema#string

P698

22344688

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

phosphorylation

P932

3302662

http://www.w3.org/2001/XMLSchema#string